105
Views
22
CrossRef citations to date
0
Altmetric
Original Research

Benralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: results from the Phase IIIb ALIZE trial

, , , , , , & show all
Pages 181-192 | Published online: 16 Aug 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Joseph W Lanario & Lorna Burns. (2021) Use of Health Related Quality of Life in Clinical Trials for Severe Asthma: A Systematic Review. Journal of Asthma and Allergy 14, pages 999-1010.
Read now

Articles from other publishers (21)

Ming-Li Chen, Tanawin Nopsopon & Ayobami Akenroye. (2023) Incidence of Anti-Drug Antibodies to Monoclonal Antibodies in Asthma: A Systematic Review and Meta-Analysis. The Journal of Allergy and Clinical Immunology: In Practice 11:5, pages 1475-1484.e20.
Crossref
Amy D. Klion. (2022) Approach to the patient with suspected hypereosinophilic syndrome. Hematology 2022:1, pages 47-54.
Crossref
Martin C. Runnstrom & F. Eun-Hyung Lee. (2022) Reply to Liao et al. : SARS-CoV-2 mRNA Vaccine Antibody Response in Patients with Asthma Receiving Biologic Therapy: A Real-World Analysis . American Journal of Respiratory and Critical Care Medicine 206:5, pages 647-648.
Crossref
Shu-Yi Liao, Anthony N. Gerber, Pearlanne Zelarney, Barry Make & Michael E. Wechsler. (2022) SARS-CoV-2 mRNA Vaccine Antibody Response in Patients with Asthma Receiving Biologic Therapy: A Real-World Analysis. American Journal of Respiratory and Critical Care Medicine 206:5, pages 644-648.
Crossref
Marek Jutel, Maria J. Torres, Oscar Palomares, Cezmi A. Akdis, Thomas Eiwegger, Eva Untersmayr, Domingo Barber, Magdalena Zemelka‐Wiacek, Anna Kosowska, Elizabeth Palmer, Stefan Vieths, Vera Mahler, Walter G. Canonica, Kari Nadeau, Mohamed H Shamji & Ioana Agache. (2022) COVID‐19  vaccination in patients receiving allergen immunotherapy (AIT) or biologicals—EAACI recommendations. Allergy 77:8, pages 2313-2336.
Crossref
Baldassarre Martire, Giorgio Ottaviano, Maria Sangerardi, Mayla Sgrulletti, Loredana Chini, Rosa Maria Dellepiane, Davide Montin, Caterina Rizzo, Claudio Pignata, Gian Luigi Marseglia & Viviana Moschese. (2022) Vaccinations in Children and Adolescents Treated With Immune-Modifying Biologics: Update and Current Developments. The Journal of Allergy and Clinical Immunology: In Practice 10:6, pages 1485-1496.
Crossref
Martin C. Runnstrom, Andrea Morrison-Porter, Mayuran Ravindran, Hannah Quehl, Richard P. Ramonell, Matthew Woodruff, Rahulkumar Patel, Caroline Kim, Natalie S. Haddad & F. Eun-Hyung Lee. (2022) Reduced COVID-19 Vaccine Response in Patients Treated with Biologic Therapies for Asthma. American Journal of Respiratory and Critical Care Medicine 205:10, pages 1243-1245.
Crossref
Chiara Gertosio, Amelia Licari, Annalisa De Silvestri, Chiara Rebuffi, Elena Chiappini & Gian Luigi Marseglia. (2022) Efficacy, immunogenicity, and safety of available vaccines in children on biologics: A systematic review and meta-analysis. Vaccine 40:19, pages 2679-2695.
Crossref
Steven J. Ackerman. 2022. Eosinophilic Lung Diseases. Eosinophilic Lung Diseases 1 18 .
Pablo Ciudad-Gutiérrez, Beatriz Fernández-Rubio & Ana Belén Guisado-Gil. (2021) Gender bias in clinical trials of biological agents for severe asthma: A systematic review. PLOS ONE 16:9, pages e0257765.
Crossref
Marco Caminati, Gabriella Guarnieri, Veronica Batani, Elena Scarpieri, Anita Finocchiaro, Fulvia Chieco-Bianchi, Gianenrico Senna & Andrea Vianello. (2021) COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control. Vaccines 9:8, pages 853.
Crossref
Oliver Pfaar, Ludger Klimek, Eckard Hamelmann, Jörg Kleine-Tebbe, Christian Taube, Martin Wagenmann, Thomas Werfel, Randolf Brehler, Natalija Novak, Norbert K. Mülleneisen, Sven Becker & Margitta Worm. (2021) COVID-19-Impfungen von Patienten mit Allergien und Typ2-entzündlichen Erkrankungen bei gleichzeitiger Antikörpertherapie (Biologika). Allergo Journal 30:5, pages 24-33.
Crossref
Fei Li Kuang & Bruce S. Bochner. (2021) Lessons learned from targeting eosinophils in human disease. Seminars in Immunopathology 43:3, pages 459-475.
Crossref
M. Idzko, R. Buhl, E. Eber, E. Hamelmann, B. Lamprecht, F. Horak, W. Pohl & C. Taube. (2021) COVID-19-Impfungen bei Biologika-Therapie von Asthma bronchiale. Pneumologie 75:04, pages 259-260.
Crossref
Scott Manetz, Irina Maric, Thomas Brown, Fei Li Kuang, Lauren Wetzler, Elizabeth Battisto & Amy D. Klion. (2021) Successful pregnancy in the setting of eosinophil depletion by benralizumab. The Journal of Allergy and Clinical Immunology: In Practice 9:3, pages 1405-1407.e3.
Crossref
Genny Chaia, Ubaldo Martín, Arturo Cortés-Telles, Fernando Morett, José Julio Gutiérrez-Mujica, Adriana Zepeda-Gómez, Alberto Hegewisch & Rogelio Ramses Hernández. (2020) Benralizumab: eficacia y seguridad en pacientes con asma grave eosinofílica.. Revista Alergia México 67.
Crossref
Anne Y. Liu. (2020) Infectious Implications of Interleukin-1, Interleukin-6, and T Helper Type 2 Inhibition. Infectious Disease Clinics of North America 34:2, pages 211-234.
Crossref
David J. Jackson, Stephanie Korn, Sameer K. Mathur, Peter Barker, Venkata G. Meka, Ubaldo J. Martin & James G. Zangrilli. (2020) Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab. Drug Safety 43:5, pages 409-425.
Crossref
Amy D. KlionSteven J. AckermanBruce S. Bochner. (2020) Contributions of Eosinophils to Human Health and Disease. Annual Review of Pathology: Mechanisms of Disease 15:1, pages 179-209.
Crossref
Jörg D. Leuppi, Peter Schmid-Grendelmeier, Thomas Rothe, Christophe von Garnier, Hans-Uwe Simon, Claudio Schuoler, Gunther Pendl & Markus Solèr. (2019) Benralizumab: Cibler le récepteur de l’IL-5 dans l’asthme sévère éosinophile. Praxis 108:7, pages 1-8.
Crossref
Jörg D. Leuppi, Peter Schmid-Grendelmeier, Thomas Rothe, Christophe von Garnier, Hans-Uwe Simon, Claudio Schuoler, Gunther Pendl & Markus Solèr. (2019) Benralizumab: Der IL-5-Rezeptor als Ziel bei schwerem eosinophilem Asthma. Praxis 108:7, pages 469-476.
Crossref